Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 juin 2021 09h05 HE | Source: Ultimovacs ASA

Ultimovacs ASCO Phase I data shows 60% ORR in advanced melanoma with UV1/pembrolizumab, supporting broad Phase II combination program

UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports expanded Phase II combination programData highlighted at ASCO in poster...
01 juin 2021 08h00 HE | Source: Ultimovacs ASA

Ultimovacs Announces Publication in The Journal of Translational Medicine on Mechanistic Rationale of UV1 Cancer Vaccine Supporting Phase 2 Study Design in Malignant Mesothelioma

OSLO, Norway, June 01, 2021 (GLOBE NEWSWIRE) -- Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, today announced that a peer-reviewed...
19 mai 2021 16h56 HE | Source: Ultimovacs ASA

Ultimovacs’ UV1 in Combination with Pembrolizumab Shows 60% Objective Response Rate in Advanced Melanoma Phase I data

UV1/pembrolizumab results in 30% complete responses plus 30% partial responsesGood safety and tolerability profile supports use of UV1 in combination treatmentsData to be presented at ASCO and...